8 completed, 5 terminated, 1 no longer available, 1 recruiting. 6 Phase 1, 6 Phase 2, 4 Phase 3, 1 Phase 4.
By phase and status
Follow casirivimab: new trials by email Literature Review of casirivimab trials Research Report on casirivimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
COVID-19 Study Assessing the Safety and Tolerability of Co-Formulated Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) in Adult Volunteers Casirivimab+Imdevimab - Healthy, Chronic Stable Illness Phase 1 Completed 45 2022-01-07 2025-10-14 Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail Casirivimab and Imdevimab Antibody Cocktail - COVID-19, Organ Transplant Phase 1 Withdrawn 2022-01-01 2022-04-22 COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19 casirivimab+imdevimab - COVID-19 Phase 1 Terminated 2 2021-12-16 2025-10-14 TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2 casirivimab with imdevimab, sotrovimab, molnupiravir - COVID-19 Completed 1178 2021-12-14 2025-12-16 COVID-19 International Drug Pregnancy Registry Antiviral Agents, Monoclonal antibody - Covid19 Recruiting 2000 2021-12-01 2025-09-26 COVID-19 Study to Evaluate Safety, Tolerability, and Efficacy of REGN14256+Imdevimab for the Treatment of COVID-19 Adult and Adolescent Patients Without Risk Factors for Progression to Severe Disease REGN14256, imdevimab, casirivimab + imdevimab - SARS-CoV-2 Phase 1 / Phase 2 Terminated 25 2021-11-08 2025-10-28 A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults casirivimab+imdevimab, Placebo - Immunocompromised Phase 3 Terminated 66 2021-10-25 2025-10-20 COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers casirivimab+imdevimab, Moderna mRNA-1273 vaccine - Healthy, Chronic Stable Illness Phase 2 Completed 295 2021-04-29 2025-10-20 Treatment of Nosocomial COVID-19 Anti-SARS-CoV-2 mAb - Covid19, Nosocomial Infection Phase 4 Terminated 46 2021-02-12 2023-04-19 COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection REGN10933+REGN10987 combination therapy, Placebo - COVID-19 Phase 2 Completed 1149 2020-12-15 2022-04-08 Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB - Covid19 Phase 2 Unknown 1000 2020-11-20 2022-03-29 ACTIV-2: A Study for Outpatients With COVID-19 bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19 Phase 2 / Phase 3 Completed 4044 2020-08-19 2024-08-02 Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19 REGN10933+REGN10987, Placebo - Healthy, Chronic Stable Illness Phase 1 Completed 974 2020-07-26 2022-01-26 COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay REGN10933 + REGN10987, Placebo - Healthy Participants Phase 3 Completed 3303 2020-07-13 2023-05-15 Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19 casirivimab+imdevimab combination therapy - COVID-19 Phase 3 Terminated 10078 2020-06-16 2023-12-21 Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19 REGN10933+REGN10987 combination therapy, Placebo - COVID-19 Phase 1 / Phase 2 Completed 2252 2020-06-10 2023-01-27 Compassionate Use of REGN-COV2 for the Treatment of COVID-19 REGN10933+REGN10987 combination therapy - COVID-19 No longer available 2023-10-03
Conditions studied COVID-19 (15) · Coronavirus Infections (6) · Coronaviridae Infections (1) · Cross Infection (1) · Nidovirales Infections (1) · RNA Virus Infections (1) · Respiratory Distress Syndrome (1) · Severe Acute Respiratory Syndrome (1) · Virus Diseases (1)
Sponsors Regeneron Pharmaceuticals (11) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Northwell Health (1) · Pregistry (1) · Sohail Rao (1) · University of Calgary (1)
Countries United States (14) · Mexico (4) · Romania (3) · Brazil (2) · Canada (2) · Moldova (2) · Argentina (1) · Chile (1) · Guatemala (1) · Netherlands (1) · Philippines (1) · Puerto Rico (1) · South Africa (1)
Top investigators Alain Tremblay (1) · Cheryl Renz, MD (1) · David Smith, MD, MAS (1) · Lewis Teperman, MD (1) · Robert Fowler (1) · Sohail Rao, MD (1) · Srinivas Murthy (1)
Results publications PMID 34473343 , PMID 35713300 , PMID 33332778 , PMID 34159343 , PMID 34159344 , PMID 34347950 , PMID 34587383 , PMID 34981077 , PMID 35029629 , PMID 35793677 , PMID 35797235 , PMID 35803290 , PMID 35895508 , PMID 35913747 , PMID 35969402 , PMID 35995785 , PMID 36210483 , PMID 36255239 , PMID 36289399 , PMID 36301549 , PMID 36378539 , PMID 36467293 , PMID 36661240 , PMID 36802755 , PMID 37068272 , PMID 37079569 , PMID 37099295 , PMID 37229174 , PMID 37279602 , PMID 37330602 , PMID 37410460 , PMID 37650230 , PMID 37650232 , PMID 37650233 , PMID 37650236 , PMID 37855026 , PMID 37973784 , PMID 38102791 , PMID 38843052 , PMID 38961047 , PMID 39018444 , PMID 39028902 , PMID 39236733 , PMID 39384241 , PMID 39974282 , PMID 40256045 , PMID 42148571